Ado-trastuzumab emtansine (Kadcyla®)


Indications for Prior Authorization:

HER2 positive, metastatic breast cancer

All of the following must be met as a condition for coverage:

Must have previous treatment with Herceptin® and taxane (separately or in combination)

This Medication is Not Approvable for the following condition(s):

Any condition not listed above as an approved indication.


Recommended dose: 3.6mg/kg IV every 3 weeks (21 day cycle) until disease progression or unacceptable toxicity

Duration of Therapy:

Initial authorization: one year


Last review date: December 3, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.